Neutralizing antibodies and methods of use thereof
AssigneeNovImmune S.A.
InventorsGreg Elson, Olivier Leger
Life of this patent
Estimating the term…
Abstract
This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins, methods of expressing and purifying soluble chimeric proteins, and methods of using soluble chimeric proteins as therapeutics, in screening assays and in the production of antibodies.
Claims6
An isolated antibody that binds a Toll-like receptor 4 (TLR4)/MD-2 complex, wherein the antibody comprises:
- (a) a variable heavy chain complementarity determining region 1 (VH CDR1) comprising the amino acid sequence DSYIH (SEQ ID NO:3);
- (b) a variable heavy chain complementarity determining region 2 (VH CDR2) comprising the amino acid sequence WTDPENVNSIYDPRFQG (SEQ ID NO:4);
- (c) a variable heavy chain complementarity determining region 3 (VH CDR3) comprising the amino acid sequence GYNGVYYAMDY (SEQ ID NO:5);
- (d) a variable light chain complementarity determining region 1 (VL CDR1) comprising the amino acid sequence SASSSVIYMH (SEQ ID NO:8);
- (e) a variable light chain complementarity determining region 2 (VL CDR2) comprising the amino acid sequence RTYNLAS (SEQ ID NO:9);
- and
- (f) a variable light chain complementarity determining region 3 (VL CDR3) comprising the amino acid sequence HQWSSFPYT (SEQ ID NO:10).
Dependencies are inferred from the claim text.